Stellantis Production In Italy Slumps 27% In H1 2025: Union Now Expects Slump In Annual Numbers

Jeep parent Stellantis NV’s (STLA) production in Italy fell by 27% to 221,885 vehicles in the first half of 2025, union Fim CISL said on Monday.

While the company’s passenger car production in Italy recorded a decrease of about 34% to 123,905 units, commercial vehicle production fell by about 16% to 97,980 units.

The union expects the carmaker to produce 440,000 vehicles across its six assembly plants in Italy this year, including 250,000 passenger cars.

Union head Ferdinando Uliano noted that the data shows further worsening as compared to an already critical 2024. In 2024, Stellantis produced 475,090 vehicles in Italy, marking a dip of 37% year-on-year and including 283,090 passenger cars.

Production fell across the company’s six final production plants in Italy in the six months through the end of June, unlike in the first half of 2024, when at least the Pomigliano factory experienced an increase in production.

While Pomigliano recorded the highest production among the six plants in the first half of 2025, it marked a fall of about 24% YoY. The Maserati Modena plant manufactured only 45 units in the period, marking a decline of about 72%.

Uliano noted that there are no signs of recovery by the end of the year, as the start of production of the hybrid Fiat 500 later this year at the Mirafiori Carrozzerie plant will be able to produce results only in 2026.

The level of production decline in 2025 is higher than expected, Uliano noted.

The union chief also urged Stellantis to clarify its strategy for the Maserati brand, including models and volumes, as the brand faces performance issues.

The carmaker is expected to announce its first-half results on July 29.

On Stocktwits, retail sentiment around Stellantis remained unmoved within ‘neutral’ territory over the past 24 hours while message volume fell from ‘high’ to ‘normal’ levels.

STLA stock is trading 5% lower as of Monday noon. The stock is down by 25% this year and by about 50% over the past 12 months.

Read Next: Artelo Biosciences Stock Soars On Strong Preclinical Data In Par With Zoloft For Experimental Depression Drug

For updates and corrections, email newsroom[at]stocktwits[dot]com.